CytomX Therapeutics (CTMX) News Today

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recomm

CytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below 50-Day Moving Average of $1.67

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has earned an average rating of "Moderate Buy" from the six analysts that are currently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy r

StockNews.com downgraded shares of CytomX Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.

CytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below Fifty Day Moving Average of $2.14

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy reco

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 8,750,000 shares, an increase of 143.1% from the April 30th total of 3,600,000 shares. Based on an average daily trading volume, of 6,480,000 shares, the short-interest ratio is presently 1.4 days.

Piper Sandler upgraded CytomX Therapeutics from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $2.25 to $3.50 in a research report on Tuesday.

StockNews.com upgraded shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday.

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been given an average recommendation of "Hold" by the five research firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and two have assigned a buy ratin

BMO Capital Markets raised their price objective on shares of CytomX Therapeutics from $3.25 to $3.59 and gave the stock a "market perform" rating in a research report on Thursday.

Wedbush upgraded shares of CytomX Therapeutics from a "neutral" rating to an "outperform" rating and set a $8.00 target price for the company in a research note on Thursday.

Jefferies Financial Group raised CytomX Therapeutics from a "hold" rating to a "buy" rating and upped their target price for the company from $2.50 to $8.00 in a report on Monday.

CytomX Therapeutics (NASDAQ:CTMX) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw some unusual options trading activity on Wednesday. Traders bought 16,565 call options on the company. This is an increase of 7,197% compared to the average daily volume of 227 call options.

BMO Capital Markets restated a "market perform" rating and set a $3.25 target price on shares of CytomX Therapeutics in a report on Wednesday.

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 3,590,000 shares, a growth of 8.1% from the March 31st total of 3,320,000 shares. Based on an average trading volume of 905,200 shares, the short-interest ratio is currently 4.0 days.

StockNews.com cut CytomX Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday.

JPMorgan Chase & Co. raised shares of CytomX Therapeutics from an "underweight" rating to a "neutral" rating in a research report on Monday.